Clinical trials
Active, not recruiting Lymphoproliferative Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| UNC Lineberger Comprehensive Cancer Center | 3 |
| Baylor College of Medicine | 2 |
| Center for International Blood and Marrow Transplant Research | 2 |
| AbbVie | 1 |
| Acerta Pharma BV | 1 |
| ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Cellectar Biosciences, Inc. | 1 |
| Fondazione Italiana Linfomi - ETS | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoproliferative Disorders | 23 |
| Neoplasms | 10 |
| Immune System Diseases | 9 |
| Lymphoma | 9 |
| Lymphoma, Non-Hodgkin | 9 |
| Immunoproliferative Disorders | 7 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 |
| Lymphatic Diseases | 7 |
| Leukemia | 6 |
| Myelodysplastic Syndromes | 6 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.